跳至主要内容
临床试验/NCT04832841
NCT04832841已完成不适用

IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation

Institute for Clinical and Experimental Medicine1 个研究点 分布在 1 个国家目标入组 753 人开始时间: 2021年3月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
753
试验地点
1
主要终点
Humoral immune response in kidney transplant recipients following anti-SARS-CoV2 mRNA vaccination.

研究概览

简要总结

The aim of this study is to assess humoral immune response in kidney transplant recipients after SARS-CoV-2 mRNA vaccine.

详细描述

TASMANIA is a single-center prospective observational study with 1000 kidney transplant recipients from Institute for Clinical and Experimental Medicine (IKEM), Prague. The primary objective of the study is to assess humoral immune response to SARS-CoV-2 mRNA vaccines in SARS-CoV-2-naive kidney transplant recipients using immunochemiluminescent assay. As comparator several cohorts will be evaluated:

  1. kidney transplant recipients with previous SARS-CoV-2 exposition verified by real-time reverse transcription polymerase chain reaction (RT-PCR)
  2. kidney transplant recipients vaccinated on waiting list (a) SARS-CoV-2 naive (b) SARS-CoV-2 previously exposed

The secondary objective is to determine clinical variables affecting antibody levels. SARS-CoV-2 anti S1/2 antibodies will be tested ≥ 15 days after the second dose of mRNA vaccines and in 3 months after the first blood sampling.

In subanalysis 50 kidney transplant recipients will be examined for a cell-mediated immune response after SARS-CoV-2 mRNA vaccine Enzyme Linked using Immuno Spot (ELISPOT) assay.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Kidney transplant recipients
  • Recipient age ≥ 18 years
  • Written Informed Consent and Consent for Processing Personal Data
  • Vaccination with two doses of SARS-CoV-2 mRNA vaccine either before or after kidney transplantation.

排除标准

  • Active SARS-CoV-2 infection.
  • Patients that received anti-SARS-CoV-2 monoclonal antibodies.
  • Active infection after vaccination
  • Monoclonal antibodies treatment ahead of antibody or cellular immunity screening

结局指标

主要结局

Humoral immune response in kidney transplant recipients following anti-SARS-CoV2 mRNA vaccination.

时间窗: 15 days-90 days

anti-spike SARS-CoV-2 IgG measured ≥15 days after vaccination

次要结局

  • Clinical variables affecting antibody levels(15 days-90 days)
  • The impact of frailty syndrom on humoral response in older kidney recipients (70+ years of age) following anti-SARS-CoV-2 mRNA vaccination(15 days-90 days)
  • Humoral immune response in kidney transplant recipients following anti-SARS-CoV2 mRNA vaccination.(3 months - 6 months)
  • Graft function after vaccination(15 days-90 days)
  • Cellular immune response in kidney transplant recipients following anti-SARS-CoV2 mRNA vaccination.(15 - 90 days)

研究者

发起方
Institute for Clinical and Experimental Medicine
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Ondřej Viklický, M.D., Ph.D.

Head of Department of Nephrology and Transplant Center

Institute for Clinical and Experimental Medicine

研究点 (1)

Loading locations...

相似试验